Pernix Therapeutics (PTX) Posts Q3 Loss of 2c/Share

Pernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($0.02), $0.02 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $31.5 million versus the consensus estimate of $28.1 million.

Pernix Therapeutics reaffirmed FY2014 guidance.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• SanDisk upgraded at JPMorgan after investor day; shares climb